Breast cancer - Treatment of early disease

Hospital Pharmacist

Volumn 11, Issue 10, 2004, Pages 415-420

  Stanley, A ^a,b  

^a SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^b Pan Birmingham Cancer Network

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ALOPECIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL TRIAL; EARLY CANCER; HUMAN; MAMMOGRAPHY; MASTECTOMY; NAUSEA; PARTIAL MASTECTOMY; REVIEW; STOMATITIS; VOMITING;

EID: 9144256091     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817-24.
2. Smith IE, A'Hern R, Coombes G, Hickish TF, Howell A, O'Brien M, Robinson A, et al. A randomised neoadjuvant chemotherapy trial of vinorelbine/epirubicin (VE) vs standard doxorubicin/cyclophosphamide (DC) in patients with 3cm diameter operable breast cancer (TOPIC 2). Proceedings of the American Society of Clinical Oncology 2003;22:21 Abs 83.
3. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Annals of Oncology 2001;12:1527-32.
4. Patterson R, Russell MH. Clinical trials of malignant disease. Part III breast cancer evaluation of post-operative radiotherapy. Journal of the Faculty of Radiology 1959;10:175-80.
5. Wallgren A, Arner O, Bergstrom J, Blomstedt B, Granberg PO, Raf L, et al. Radiation therapy in operable breast cancer: results from the Stockholm trial on adjuvant radiotherapy. International Journal of Radiation Oncology Biology and Physics 1986;12:533-7.
6. Cuzick J, Stewart H, Peto R, Fisher B, Kaae S, Johansen H, et al. Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. Cancer Treatment Reports 1987;71:7-14.
7. Cuzick J, Stewart H, Peto R, Baum M, Fisher B, Host H, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treatment Reports 1987;71:15-29.
8. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. New England Journal of Medicine 1995;333:1444-55.
9. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000;355:1757-70.
10. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy Danish Breast Cancer Cooperative Group 82b Trial. New England Journal of Medicine 1997;337:949-55.
11. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. New England Journal of Medicine 1997;337:956-62.
12. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641-8.
13. Recht A, Bartelink H, Fourquet A, Fowble B, Haffty BG, Harris JR. Postmastectomy radiotherapy: questions for the twenty-first century. Journal of Clinical Oncology 1998;16:2886-9.
14. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
15. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
16. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 2003;349:1793-802.
17. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. New England Journal of Medicine 1976;294:405-10.
18. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
19. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. Journal of Clinical Oncology 1998;16:2651-8.
20. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognosis factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. Journal of Clinical Oncology 2001;19:602-11.
21. Poole CJ, Earl HM, Dunn JA, Hiller L, Bathers S, Spooner D, et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proceedings of the American Society of Clinical Oncology 2003;22:4 Abs 13.
22. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improving outcomes for adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regime for patients with node-positive primary breast-cancer. Journal of Clinical Oncology 2003;21:976-83.
23. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proceedings of the American Society of Clinical Oncology 2003;22:4 Abs 12.
24. Nabholtz JM, Pienkowsky T, Mackey J, Pawlicki M, Guastalla J-P, Vogel C, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proceedings of the American Society of Clinical Oncology 2002;21:36a Abs 141.